Evidence map›Paper›PMID 41970475›Full record

ReviewCirculation reports2026

Pulsed Field Ablation for Atrial Fibrillation in Japan: Current Status and Future Perspectives.

Shinsuke Miyazaki

Abstract readReview
In one paragraph

Review in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Shinsuke MiyazakiDepartment of Cardiovascular Medicine, Institute of Science Tokyo Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Catheter ablation of atrial fibrillation (AF) is an established therapeutic strategy, with pulmonary vein isolation as the cornerstone of ablative therapy. Although radiofrequency and cryothermal energies have been the main energy sources, the past decade has witnessed remarkable scientific progress and growing interest in pulsed field ablation (PFA) as a novel energy modality, leading to the recent clinical adoption of PFA technologies for AF treatment. In Japan, PFA was introduced into clinical practice in 2024 and has been rapidly accepted. Unlike traditional thermal energies, PFA uses pulsed electric fields to induce irreversible electroporation, selectively targeting myocardial tissue while preserving adjacent structures from thermal or mechanical injury. Offering procedural efficacy comparable to conventional thermal ablation, PFA distinguishes itself by enabling shorter procedure times and reducing the risk of complications. This review summarizes the mechanisms of PFA, currently available systems in Japan, reported clinical outcomes and complications, as well as limitations and future perspectives.

Indexed as

Atrial fibrillationCatheter ablationPulmonary vein isolationPulsed field ablation

Identifiers

PMID41970475
PMCPMC13065459

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.